Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

Maher Albitar, Julie Marie Vose, Marcella M. Johnson, Kim Ann Do, Amanda Day, Iman Jilani, Hagop Kantarjian, Michael Keating, Susan M. O'Brien, Srdan Verstovsek, James Olen Armitage, Francis J. Giles

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Plasma levels of beta-2 microglobulin (β2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n = 65) and HD (n = 37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and β2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of β2M. However, multivariate analysis incorporating β2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6 μg/100 mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as β2M. In HD patients, β2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that β2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from β2M as an indicator of clinical behavior in HD.

Original languageEnglish (US)
Pages (from-to)139-145
Number of pages7
JournalLeukemia Research
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

HLA Antigens
Hodgkin Disease
Non-Hodgkin's Lymphoma
Biological Phenomena
beta 2-Microglobulin
Tumor Biomarkers
Multivariate Analysis
Survival
Serum

Keywords

  • Beta-2 microglobulin
  • Hodgkin's disease
  • Human leukocyte antigen-class I
  • Immune modulation
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. / Albitar, Maher; Vose, Julie Marie; Johnson, Marcella M.; Do, Kim Ann; Day, Amanda; Jilani, Iman; Kantarjian, Hagop; Keating, Michael; O'Brien, Susan M.; Verstovsek, Srdan; Armitage, James Olen; Giles, Francis J.

In: Leukemia Research, Vol. 31, No. 2, 01.02.2007, p. 139-145.

Research output: Contribution to journalArticle

Albitar, M, Vose, JM, Johnson, MM, Do, KA, Day, A, Jilani, I, Kantarjian, H, Keating, M, O'Brien, SM, Verstovsek, S, Armitage, JO & Giles, FJ 2007, 'Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease', Leukemia Research, vol. 31, no. 2, pp. 139-145. https://doi.org/10.1016/j.leukres.2006.02.013
Albitar, Maher ; Vose, Julie Marie ; Johnson, Marcella M. ; Do, Kim Ann ; Day, Amanda ; Jilani, Iman ; Kantarjian, Hagop ; Keating, Michael ; O'Brien, Susan M. ; Verstovsek, Srdan ; Armitage, James Olen ; Giles, Francis J. / Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. In: Leukemia Research. 2007 ; Vol. 31, No. 2. pp. 139-145.
@article{cd4b41b3a25640399758c9fcb34a9726,
title = "Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease",
abstract = "Plasma levels of beta-2 microglobulin (β2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n = 65) and HD (n = 37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and β2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of β2M. However, multivariate analysis incorporating β2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6 μg/100 mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as β2M. In HD patients, β2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that β2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from β2M as an indicator of clinical behavior in HD.",
keywords = "Beta-2 microglobulin, Hodgkin's disease, Human leukocyte antigen-class I, Immune modulation, Non-Hodgkin's lymphoma",
author = "Maher Albitar and Vose, {Julie Marie} and Johnson, {Marcella M.} and Do, {Kim Ann} and Amanda Day and Iman Jilani and Hagop Kantarjian and Michael Keating and O'Brien, {Susan M.} and Srdan Verstovsek and Armitage, {James Olen} and Giles, {Francis J.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2006.02.013",
language = "English (US)",
volume = "31",
pages = "139--145",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

AU - Albitar, Maher

AU - Vose, Julie Marie

AU - Johnson, Marcella M.

AU - Do, Kim Ann

AU - Day, Amanda

AU - Jilani, Iman

AU - Kantarjian, Hagop

AU - Keating, Michael

AU - O'Brien, Susan M.

AU - Verstovsek, Srdan

AU - Armitage, James Olen

AU - Giles, Francis J.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Plasma levels of beta-2 microglobulin (β2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n = 65) and HD (n = 37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and β2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of β2M. However, multivariate analysis incorporating β2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6 μg/100 mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as β2M. In HD patients, β2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that β2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from β2M as an indicator of clinical behavior in HD.

AB - Plasma levels of beta-2 microglobulin (β2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n = 65) and HD (n = 37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and β2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of β2M. However, multivariate analysis incorporating β2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6 μg/100 mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as β2M. In HD patients, β2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that β2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from β2M as an indicator of clinical behavior in HD.

KW - Beta-2 microglobulin

KW - Hodgkin's disease

KW - Human leukocyte antigen-class I

KW - Immune modulation

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33845208244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845208244&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.02.013

DO - 10.1016/j.leukres.2006.02.013

M3 - Article

VL - 31

SP - 139

EP - 145

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -